NCT06992713View on ClinicalTrials.gov

A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 18, 2025

Primary Completion Date

September 4, 2026

Study Completion Date

November 30, 2026

Conditions
Advanced Solid Tumor
Interventions
DRUG

H1710 for Injection

Injection.

Trial Locations (3)

100142

RECRUITING

Beijing Cancer Hospital, Beijing

100144

RECRUITING

Peking University Shougang Hospital, Beijing

Unknown

RECRUITING

Shanghai East Hospital, Shanghai

All Listed Sponsors
lead

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

INDUSTRY